Resources
70 Results (showing 1 - 10)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 5/3/2021 (updated 4/10/2024)
The U.S. Food and Drug Administration (FDA) announced on April 30, 2021 the approval of a higher dose naloxone hydrochloride nasal spray product to treat opioid overdose. The newly approved product delivers 8 milligrams (mg) of naloxone into the nasal cavity. The FDA had previously approved 2 mg and 4 mg naloxone nasal spray products.
Naloxone is a medicine that can be administered by individuals with or without medical training to help reduce opioid overdose deaths. If naloxone is administered quickly, it can counter the opioid overdose effects, usually within minutes. A higher dose of naloxone provides an additional option in the treatment of opioid overdoses.
Posted 3/2/2021 (updated 4/4/2024)
This session will walk through the strategic plan template provided by JBS International in the Grantee Onboarding Packet for HRSA RCORP-Planning Grantees. During this workshop style webinar, facilitators will walk grantees through the template section by section, discussing the required elements and providing examples of each section. Grantees will learn how to use their data to determine problem statements, goals, objectives, and outcomes for their strategic plan as well as how to include metrics to successfully track their progress.
Posted 10/26/2021 (updated 4/3/2024)
Posted 10/14/2021 (updated 4/3/2024)
Stimulant intoxication, withdrawal, and psychosis have accepted and established treatment strategies. Several lifesaving harm reduction interventions/services are available. There are no Food and Drug Administration-approved medications for treatment of stimulant use disorder, although several are promising. Behavioral treatment, especially the use of contingency management (and other approaches with supportive evidence), has by far the best evidence of effectiveness. The presenter reviewed topics of importance to clinicians treating individuals with stimulant use disorder.
Rick Rawson, PhD, University of Vermont Rural Center of Excellence
Posted 10/14/2021 (updated 4/3/2024)
Representatives from the JBS/HRSA evaluation team presented information on Performance Improvement Measurement System deliverables and answer grantee questions.
Rebecca Schachtner, PhD, JBS International
Posted 11/18/2020 (updated 4/3/2024)
Healthcare provider burnout can lead to substance use disorder (SUD) and significant consequences for the individual, patients, and healthcare institutions. This webinar explored healthcare provider burnout, the scope of SUD in the medical community, and current pathways to recovery.
Posted 11/9/2020 (updated 4/3/2024)
This webinar will provide an overview of racial and ethnic minority members of rural communities; describe the relationship between social determinants of health, health disparities, health equity, and rural racial and ethnic minority populations; and propose characteristics for an effective engagement and collaboration plan for working with these populations. The presenter will discuss strategies for enhancing engaging and collaborating with rural racial and ethnic minority populations and review available resources and tools.
Posted 10/29/2020 (updated 4/3/2024)
Triumph over the opioid epidemic requires ALL traditional and non-traditional partners to come to the table. Join us to explore strategies for increasing the reach and sustainability of rural community coalitions by ensuring the right partners are at your table and can contribute to solving this crisis rather than be consumed by it.
Posted 10/20/2020 (updated 3/29/2024)
During this welcome webinar, FORHP program coordinator, project officers, and supervisory grants management specialist will review program guidelines and updates, introduce the Technical Assistance Leads from JBS International, and answer initial questions grantees may have to get started with their projects.
Posted 9/30/2020 (updated 3/29/2024)
This packet presents Implementation II grantees with tools and strategies to support implementation activities that expand the options for SUD/OUD services across the care spectrum, thereby helping rural residents in your community to prevent SUD/OUD, access treatment, and move toward recovery.